The European Medicines Agency (EMA) today recommended adding a warning for two types of heart inflammation to Novavax’s COVID-19 vaccine, marketed under the brand names Nuvaxovid and Covovax, based on a small number of cases reported in those who received the vaccine.
The Canadian official with final say on whether or not a vaccine gets approved in the country says there isn’t a threshold that would cause the removal of COVID-19 injections from circulation, court documents reveal.